DexCom, Inc. (NASDAQ:DXCM) Shares Sold by UniSuper Management Pty Ltd

UniSuper Management Pty Ltd reduced its holdings in DexCom, Inc. (NASDAQ:DXCM) by 66.7% during the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 38,177 shares of the medical device company’s stock after selling 76,404 shares during the quarter. UniSuper Management Pty Ltd’s holdings in DexCom were worth $2,969,000 as of its most recent filing with the SEC.

A number of other large investors have also recently bought and sold shares of DXCM. Geode Capital Management LLC boosted its stake in DexCom by 2.2% during the 3rd quarter. Geode Capital Management LLC now owns 9,937,604 shares of the medical device company’s stock valued at $664,056,000 after purchasing an additional 214,136 shares during the period. Jennison Associates LLC grew its holdings in shares of DexCom by 10.3% in the 4th quarter. Jennison Associates LLC now owns 7,643,757 shares of the medical device company’s stock worth $594,455,000 after acquiring an additional 710,858 shares during the last quarter. Groupama Asset Managment raised its holdings in DexCom by 1.1% during the 3rd quarter. Groupama Asset Managment now owns 2,851,556 shares of the medical device company’s stock worth $1,912,000 after buying an additional 31,358 shares during the period. Charles Schwab Investment Management Inc. lifted its stake in DexCom by 3.3% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 2,825,206 shares of the medical device company’s stock valued at $219,716,000 after buying an additional 91,051 shares in the last quarter. Finally, Artisan Partners Limited Partnership boosted its holdings in shares of DexCom by 12.2% in the fourth quarter. Artisan Partners Limited Partnership now owns 1,853,565 shares of the medical device company’s stock worth $144,152,000 after buying an additional 201,181 shares during the period. Institutional investors own 97.75% of the company’s stock.

Analyst Ratings Changes

A number of analysts have recently issued reports on the company. Wells Fargo & Company restated an “overweight” rating on shares of DexCom in a report on Saturday, March 8th. Cfra Research upgraded DexCom to a “hold” rating in a research report on Friday, March 21st. Redburn Atlantic upgraded DexCom from a “neutral” rating to a “buy” rating and upped their target price for the company from $85.00 to $115.00 in a report on Monday, February 3rd. Morgan Stanley increased their price target on shares of DexCom from $75.00 to $82.00 and gave the stock an “equal weight” rating in a research report on Friday, February 14th. Finally, Baird R W raised DexCom from a “hold” rating to a “strong-buy” rating in a research report on Thursday, January 16th. Five equities research analysts have rated the stock with a hold rating, thirteen have given a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $99.82.

DexCom Price Performance

Shares of NASDAQ:DXCM opened at $67.74 on Friday. The firm has a 50 day moving average of $82.32 and a 200-day moving average of $77.07. The company has a current ratio of 1.47, a quick ratio of 1.28 and a debt-to-equity ratio of 0.59. DexCom, Inc. has a 12 month low of $62.34 and a 12 month high of $141.99. The stock has a market capitalization of $26.47 billion, a PE ratio of 47.37, a PEG ratio of 2.30 and a beta of 1.28.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings data on Thursday, February 13th. The medical device company reported $0.45 earnings per share for the quarter, missing the consensus estimate of $0.50 by ($0.05). DexCom had a return on equity of 30.14% and a net margin of 14.29%. On average, equities research analysts predict that DexCom, Inc. will post 2.03 EPS for the current fiscal year.

Insider Activity at DexCom

In other news, EVP Jereme M. Sylvain sold 2,090 shares of the company’s stock in a transaction that occurred on Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total value of $181,641.90. Following the completion of the transaction, the executive vice president now owns 83,526 shares of the company’s stock, valued at $7,259,244.66. This represents a 2.44 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, COO Jacob Steven Leach sold 2,634 shares of DexCom stock in a transaction that occurred on Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total transaction of $228,920.94. Following the sale, the chief operating officer now owns 268,644 shares in the company, valued at approximately $23,347,850.04. This represents a 0.97 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 105,009 shares of company stock valued at $8,044,178. 0.30% of the stock is owned by insiders.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.